TFFP
Income statement / Annual
Last year (2023), TFF Pharmaceuticals, Inc.'s total revenue was $733,871.00,
and the percentage change from the previous year is not available.
In 2023, TFF Pharmaceuticals, Inc.'s net income was -$21.24 M.
See TFF Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
Operating Revenue |
$733,871.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$502,480.00
|
$388,221.00
|
$111,453.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$231,391.00
|
-$388,221.00
|
-$111,453.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0.32
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$11.56 M
|
$18.50 M
|
$21.30 M
|
$10.68 M
|
$8.82 M
|
$848,809.00
|
$0.00
|
$229,259.00
|
General & Administrative Expenses |
$10.57 M
|
$13.80 M
|
$10.57 M
|
$8.01 M
|
$3.17 M
|
$0.00
|
$178,605.00
|
$0.00
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$10.57 M
|
$13.80 M
|
$10.57 M
|
$8.01 M
|
$3.17 M
|
$3.05 M
|
$178,605.00
|
$141,111.00
|
Other Expenses |
$0.00
|
-$495,805.00
|
-$88,161.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$22.13 M
|
$31.80 M
|
$31.79 M
|
$18.69 M
|
$11.99 M
|
$3.90 M
|
$178,605.00
|
$370,370.00
|
Cost And Expenses |
$22.63 M
|
$31.80 M
|
$31.79 M
|
$18.69 M
|
$11.99 M
|
$3.90 M
|
$178,605.00
|
$370,370.00
|
Interest Income |
$0.00
|
$26,728.00
|
$51,232.00
|
$126,416.00
|
$117,329.00
|
$55,960.00
|
$0.00
|
$0.00
|
Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$502,480.00
|
$388,221.00
|
$111,453.00
|
$206,297.00
|
$171,860.00
|
$0.00
|
$52,516.00
|
$0.00
|
EBITDA |
-$20.74 M |
-$31.41 M |
-$30.93 M |
-$18.69 M |
-$11.99 M |
-$3.90 M |
-$178,605.00 |
-$370,370.00 |
EBITDA Ratio |
-28.26
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
-29.83
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
$651,431.00
|
$26,728.00
|
$747,946.00
|
$126,416.00
|
$117,329.00
|
$55,964.00
|
$0.00
|
$0.00
|
Income Before Tax |
-$21.24 M
|
-$31.77 M
|
-$31.04 M
|
-$18.57 M
|
-$11.87 M
|
-$3.84 M
|
-$178,605.00
|
-$370,370.00
|
Income Before Tax Ratio |
-28.95
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$0.00
|
-$26.73
|
-$51,232.00
|
-$126,416.00
|
-$117,329.00
|
$0.00
|
-$52,521.00
|
$0.00
|
Net Income |
-$21.24 M
|
-$31.77 M
|
-$30.99 M
|
-$18.44 M
|
-$11.75 M
|
-$3.84 M
|
-$178,605.00
|
-$370,370.00
|
Net Income Ratio |
-28.95
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
EPS |
-11.85 |
-26.49 |
-31.21 |
-22.57 |
-42.55 |
-5.21 |
-0.01 |
-0.5 |
EPS Diluted |
-11.85 |
-26.49 |
-31.21 |
-22.57 |
-42.55 |
-5.21 |
-0.01 |
-0.5 |
Weighted Average Shares Out |
$1.79 M
|
$1.20 M
|
$992,838.00
|
$817,006.00
|
$276,199.00
|
$738,039.00
|
$17.83 M
|
$738,039.00
|
Weighted Average Shares Out Diluted |
$1.79 M
|
$1.20 M
|
$992,838.00
|
$817,006.00
|
$276,199.00
|
$738,039.00
|
$17.83 M
|
$738,039.00
|
Link |
|
|
|
|
|
|
|
|